Clinical trial
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
NCT04823624 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 27, 2022
- Completion date
- November 1, 2025
- Enrollment
- 10 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.